尼古丁胺通过调节炎症反应和增强脂质代谢来缓解内脏莱什曼病
Qi Zhou1, Zhiwan Zheng1,2, Shuangshuang Yin1
1Department of Pathogenic Biology, West China School of Basic Medical Sciences and Forensic Medicine, Sichuan University, Chengdu, Sichuan, China.
Parasites & vectors
|July 6, 2024
概括
尼古丁胺 (NAM) 通过减少寄生虫负载和改善小鼠肝脏健康来治疗内脏莱什曼病 (VL) 是有前途的. 这种安全且具有成本效益的维生素可能为VL提供新的治疗选择.
科学领域:
- 免疫学 免疫学 免疫学
- 寄生虫学的寄生虫学
- 生物化学 生物化学
背景情况:
- 目前的内脏莱什曼病 (VL) 治疗有效性有限,副作用显著.
- 尼古丁胺 (NAM) 是一种安全且价格合理的维生素,在体外已表现出抗莱什曼的活性.
- 尼古丁胺胺在Leishmania感染中的体内治疗潜力在很大程度上仍未被探索.
研究的目的:
- 在小鼠模型中评估尼古丁胺胺作为VL治疗干预措施的疗效,该干预措施是由于Leishmania infantum引起的.
- 调查尼古丁胺胺治疗效果背后的分子机制.
主要方法:
- 在Leishmania婴儿小鼠模型中评估尼古丁胺胺的疗效.
- 分析细胞因子,淋巴细胞子集和肝脏RNA测序.
- 验证关键的分子通路,包括脂肪酸β-氧化.
主要成果:
- 尼古丁胺治疗显著改善了肝炎和肝脏病理.
- 寄生虫减少率在肝脏达到79.7%,在脏达到86.7%.
- 尼古丁胺调节了免疫反应,增强了脂肪酸β-氧化,并促进了脂质平衡.
结论:
- 尼古丁胺在小鼠中证明了对莱什曼尼亚感染的安全性和治疗效果.
- 研究结果表明,尼古丁胺胺可能成为治疗内脏莱什曼病的可行药物.
相关概念视频
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
1.0K
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
1.0K
01:19Antiasthma Drugs: Leukotriene Modifiers
849
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
849